A strong linear relationship was observed between CTR values across brain regions. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
28,580 Alzheimer's and dementia studies in plain English, each scored out of 100.
A strong linear relationship was observed between CTR values across brain regions. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
We found no significant changes in substantia nigra or cortex flortaucipir uptake in Parkinson's disease patients over two years and no association with changes in cognitive symptoms. 3 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source
Neocortical tracer retention was highly comparable using both SUVR and distribution volume ratio-1 values obtained from dynamic scans. 5 key findings →
Participants: 18 Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer's disease is defined by the presence of β-amyloid plaques and neurofibrillary tau tangles potentially preceding clinical symptoms by many years. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
17 out of 33 patients were scored as FBB-PET positive. 5 key findings →
Participants: 33 Evidence: low
Full summary, score breakdown and related studies → Original source
Visual assessment and semiquantitative analysis provide highly congruent results, thereby enhancing reader confidence and improving scan interpretation. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Within each tracer, GMM-derived amyloid negative (A-) CL distributions were similar across cohorts. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Forty-four consecutive patients with clinical evidence of dementia, were retrospectively evaluated. 5 key findings →
Participants: 44 Evidence: low
Full summary, score breakdown and related studies → Original source
Among the 12 patients with PPA syndrome, 8 (66.7%) were considered as amyloid positive. 5 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
Dual-phase amyloid PET is considered a useful protocol to study patients with cognitive impairment. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Studies have demonstrated that the clinical manifestations of Alzheimer's disease (AD) are associated with abnormal connections in either functional connectivity networks (FCNs) or structural connectivity networks (SCNs). 4 key findings →
Participants: 46 Evidence: low
Full summary, score breakdown and related studies → Original source
Examination of brain structural and functional abnormalities in amnestic mild cognitive impairment (aMCI) has the potential to enhance our understanding of the initial pathophysiological changes in dementia. 3 key findings →
Participants: 48 Evidence: low
Full summary, score breakdown and related studies → Original source
An AD diagnostic accuracy of 91.9% was achieved by using a hybrid meta-ROI consisting of thicknesses of entorhinal and middle temporal cortices, and the volumes of the hippocampus and inferior lateral ventricles. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The retina, an anatomical extension of the brain, forms physiological connections with the visual cortex of the brain. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Changes in PCC functional connectivity comprised bidirectional alterations in the resting networks in AD-affected brains, and the impaired resting functional connectivity seemed to change with AD progression. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
18 F-PI-2620 showed peak brain uptake around 5 min after injection and fast washout from nontarget regions. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Studies suggest a link between bone loss and Alzheimer's disease. 3 key findings →
Participants: 71 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The discordant topography between atrophy and hypometabolism reported in AD is already present at the aMCI stage. 4 key findings →
Participants: 20 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Clinical, neuropsychological, and imaging profiles can contribute to accurate antemortem diagnosis in FTD. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
A 7-min window, corresponding to minutes 1-8 (frames 5-15), produced the highest voxelwise correlation between (18)F-FDG and pPIB (R = 0.78 ± 0.05). 4 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Atrophy of the CC differentiates HE and ID from AD subjects and tracks the cognitive decline of this disease. 4 key findings →
Design: cross-sectional Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The association of neurofibrillary tangles with delayed verbal recall may reflect associated hippocampal atrophy. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Resting state functional magnetic resonance imaging (fMRI) was used to measure whole brain functional connectivity within specific networks hypothesised to be more affected in dementia with Lewy bodies (DLB) (a disease characterised by prominent attentional deficits, spontaneous motor features of parkinsonism and depression) than in Alzheimer׳s disease (AD) and controls. 4 key findings →
Participants: 68 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Spatial analyses localised early hippocampal tau-PET signal predominantly to the anterior CA1. 5 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The accumulation of pathological misfolded tau is a feature common to a collective of neurodegenerative disorders known as tauopathies, of which Alzheimer's disease (AD) is the most common. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,580 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,580 records, built mostly from automated pulls of Europe PMC (62.2% of the library) and OpenAlex (17.8%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.6% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →